Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
so many day traders its so stupid just buy and hold
the spread and L2 hasnt moved since the price flux from the open... something big IS COMING
.25c today ?
I'M LITERALLY TROLLING YOU OLD TIMER 😂
THIS IS STRAIGHT UP WRONG THINKING. STOCKS ARE FORWARD LOOKING NOT THIS.
TOLD YALL OLD TIMERS
"We are thrilled about our license and commercialization agreement for crofelemer with Jaguar," said Abidin Gülmüs, GEN's CEO. "GEN's business model centers on partnering with global innovator pharmaceutical companies like Jaguar to bring therapies to our territories to serve significant unmet medical needs."
"This initiative underscores Jaguar's mission and common vision with GEN to provide patients around the world with access to prescription pharmaceuticals for essential supportive care and management of neglected symptoms across multiple complicated disease states such as cancer, SBS, and MVID."
GET REKT OLD TIMER YOU AINT GETTING IN LOW ANYMORE CRY ME A RIVER OLD MAN
14.2M MC now !
reversal time
.10c soon IMO
news soon? MC and OS just changed on charts
165M OS !
MC just increased to 13.4M. . .
Rachel Zolot Schwartz(JAGX) -> Scott Gottlieb(PFIZER)
Rachel Zolot Schwartz(JAGX) -> Scott Gottlieb(PFIZER)
Ms. Schwartz has more than 15 years of commercial and business development experience both within the pharmaceutical industry as well as in consulting. Prior to joining Volastra, she worked in business development at Pfizer, where she led the commercial assessments for all oncology deals, notably including the $11B acquisition of Array BioPharma in 2019. During her time in business development, she also completed transactions to externalize medicines that had been deprioritized by Pfizer.
Pfizer of WHOEVER would have to offer Billions for this to LISA for a cash buyout deal. There is going to be wars going on over this drug ladies and gentleman BIDDING WARS on whos going to get to help!
Pfizer might play a huge role in this somehow, if you look at the employees of the company and track there connections It leads to a Pfizer aquisition.....
Pfizer Inc would buy Array Biopharma Inc for $10.64 billion in cash, a deal it hopes will help make it a leader in colon cancer and build up its pipeline of oncology drugs.
Similar story playing out with JAGX read this.
In May 2019, Array announced results from the interim analysis of the Phase 3 BEACON mCRC trial: The second-or-third-line treatment with the BRAFTOVI triplet combination (BRAFTOVI + MEKTOVI + cetuximab) showed statistically significant improvement in overall response rate and overall survival compared to the control ...Jun 17, 2019
When did Pfizer acquire Array BioPharma?
The acquisition of Colorado-based biotech Array BioPharma in July 2019 sets the stage for Pfizer to create a potentially industry-leading franchise for colorectal cancer alongside the company's leadership in breast and prostate cancers.
Crofelemer is an oral agent that relieves diarrhea through normalizing fluid and electrolyte balance in the GI tract. The principal investigator and co-investigators identified are from MD Anderson Cancer Center. Crofelemer has received orphan-drug designation in the US and European Union for SBS
Crofelemer has received orphan-drug designation in the European Union for Microvillus Inclusion Disease (MVID), a rare congenital diarrheal disorder (CDD) condition.
NP-300 is a second-generation antisecretory agent for symptomatic relief of diarrhea from cholera. Up to
4,000,000 cases
of cholera worldwide. Napo Pharmaceuticals’ Investigational New Drug (IND) application for NP-300 for the symptomatic treatment and relief from infectious diarrhea from pathogens such as Vibrio cholerae, the bacterium that causes cholera, was activated by the US Food and Drug Administration in September 2022. In support of this IND, Napo Pharmaceuticals received partial financial support for certain IND enabling preclinical toxicity studies by the National Institute of Allergy and Infectious Diseases (NIAID). NIAID is part of the National Institutes of Health.
Sponsors and Collaborators
Napo Pharmaceuticals, Inc.
Principal Investigator: Pablo Okhuysen, MD M.D. Anderson Cancer Center
Study Chair: Pravin Chaturvedi, PhD Napo Pharmaceuticals
Locations
Hide Hide 52 study locations
United States, Arizona
Arizona Oncology Associates PC - HAL
Prescott, Arizona, United States, 86314
United States, California
Pacific Cancer Medical Center Inc
Anaheim, California, United States, 92801
The Oncology Institute of Hope and Innovation
Corona, California, United States, 92882
The Oncology Institute of Hope and Innovation
Glendale, California, United States, 91204
PIH Health Whittier Hospital
Whittier, California, United States, 90602
United States, Colorado
SCL Health Research Institute
Lafayette, Colorado, United States, 80218
United States, Florida
GenesisCare USA
Aventura, Florida, United States, 33180
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida, United States, 32909
BRCR Global
Plantation, Florida, United States, 33322
Advanced Research Institute
Saint Petersburg, Florida, United States, 33710
United States, Maryland
American Oncology Partners of Maryland
Bethesda, Maryland, United States, 20817
United States, Minnesota
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States, 55404
United States, Nebraska
Nebraska Methodist Hospital
Omaha, Nebraska, United States, 68114
United States, New York
Jacobi Medical Center
Bronx, New York, United States, 10461
North Shore Hematology Oncology Associates dba New York Cancer and Blood Specialists
Port Jefferson Station, New York, United States, 11776
United States, Ohio
Gabrail Cancer Research
Canton, Ohio, United States, 44718
United States, Oregon
Oregon Health & Science University (OHSU) Knight Cancer Institute
Portland, Oregon, United States, 97239
United States, Tennessee
The West Clinic Research
Germantown, Tennessee, United States, 38138
United States, Texas
Texas Oncology - Denison
Denison, Texas, United States, 75020
Texas Oncology, P.A. - Flower Mound
Flower Mound, Texas, United States, 75028
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Texas Oncology - New Braunfels
New Braunfels, Texas, United States, 78130
Texas Oncology - Plano East
Plano, Texas, United States, 75075-7787
Texas Oncology - Gulf Coast
Webster, Texas, United States, 77598
United States, Virginia
Inova Schar Cancer Institute
Fairfax, Virginia, United States, 22031
Shenandoah Oncology Associates
Winchester, Virginia, United States, 22601
United States, Washington
MultiCare Institute for Research and Innovation
Tacoma, Washington, United States, 98405
Argentina
Fleischer Medical Center
Buenos Aires, Argentina, 1414
Medical Center Austral
Buenos Aires, Argentina, C1019ABS
Buenos Aires British Hospital
Buenos Aires, Argentina
Cordoba Oncology Institute (IONC)
Córdoba, Argentina
Center of Nuclear and Molecular Medicine of Entre Rios (CEMENER)
Paraná, Argentina, 3100
CEDIT Diagnostic and Treatment Center
Salta, Argentina
Isis Specialized Clinic
Santa Fe, Argentina, S3000FFV
9 of July Sanatorium
Tucuman, Argentina, 4000
Georgia
LLC "Todua Clinic"
Tbilisi, Georgia, 0112
Archangel St. Michael Multiprofile Clinical Hospital LTD
Tbilisi, Georgia, 0159
JSC K. Eristavi National Center of Experimental and Clinical Surgery
Tbilisi, Georgia, 0159
Malkhaz Katsiashvili Multiprofile Emergency Medicine Center LLC
Tbilisi, Georgia, 0172
LTD Caucasus Medical Centre
Tbilisi, Georgia, 0186
Serbia
Clinical Hospital Center Bezanijska Kosa
Belgrade, Serbia, 11 080
National Cancer Research Center
Belgrade, Serbia, 11000
University Clinical Center Kragujevac
Kragujevac, Serbia, 34 000
University Clinical Center Nis
Nis, Serbia, 18 000
Institute of Pulmonary Diseases of Vojvodina
Sremska Kamenica, Serbia, 21204
Oncology Institute of Vojvodina (IOV)
Sremska Kamenica, Serbia, 21204
Taiwan
Changhua Christian Hospital
Changhua, Taiwan, 500
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung, Taiwan
China Medical University Hospital
Taichung, Taiwan, 404332
Chi Mei Medical Center - LiouYing Branch
Tainan, Taiwan, 736402
National Taiwan University Hospital
Taipei, Taiwan, 100226
Taipei Veterans General Hospital
Taipei, Taiwan, 112201
Sponsors and Collaborators
Napo Pharmaceuticals, Inc.
Sponsor:
Napo Pharmaceuticals, Inc.
Information provided by (Responsible Party):
Napo Pharmaceuticals, Inc.
THEY KNOW THE DATA PEOPLE ITS NOT THAT HARD TO FIGURE OUT THIS WAS A SHARE GRAB, THEY CAN VOTE ON R/S ALL THEY WANT ITS JUST FEAR
100k at the ask holding this back serioursly folks???
panic sellers hahaha itts almost here🥰
its almost time, tick tock. . .
Ill tell you what I think, screw the data, screw the p value, My Ai scanner is picking up possible partnership with a big time biotech company(partnership)...
its been pinged for 2 hours now, somethings up
something massive is about to unfold. . .
15M volume, dark pool really trying here
they had to hold this down a little bit longer someone's wire transfer took to long lmfao
since they made a “mistake” in their PR I guess we are now looking at Q3 or Q4 for phase 3 data. I see the RS is probable in April. No freakin way will this get above $1 in April. We all know they also do an offering on the side. That’s a given. The RS numbers look kind of silly. 100 to 1?? Why not 500 to 1? After the offering this will b3 below $1 again.
gues well try next week i guess we re buy at .05 😭
SELL ALL SHARES THIS IS GOING TO .05C, POO POO STOCK FOR SURE
PLEASE SELL YOUR SHARES THEN
10/4 ROGER THAT ITS COMING THOUGH
YOU LACK INTELLIGENCE😁 YOURE JUST MAD YOU CANT STEAL SHARES ANYMORE
CANT WAIT FOR YOUR OLD TIMER EYES TO OPEN COME 8:30!
.10c by open today